Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility

The first vaccine against SARS-CoV-2 made available in Italy has been BNT162b2, the two-dose mRNA-based vaccine developed by Pfizer-BioNTech. The ASST Fatebenefratelli-Sacco hospital is located in one of the areas most affected by the pandemic, and to date over 2000 healthcare professionals have bee...

Fuld beskrivelse

Bibliografiske detaljer
Main Authors:	Michele Gringeri, Giulia Mosini, Vera Battini, Gianluca Cammarata, Greta Guarnieri, Carla Carnovale, Emilio Clementi, Sonia Radice
Format:	Article
Sprog:	English
Udgivet:	Taylor & Francis Group 2021-09-01
Serier:	Human Vaccines & Immunotherapeutics
Fag:	covid-19 bnt162b2 vaccine pharmacovigilance eudravigilance real-world data
Online adgang:	http://dx.doi.org/10.1080/21645515.2021.1917236

Lignende værker

Adverse Reactions to Evolocumab: Analysis of Real-World Data from EudraVigilance
af: Fabrizio Calapai, et al.
Udgivet: (2024-03-01)

Safety profile of tirzepatide: A real-world pharmacovigilance analysis of EudraVigilance database
af: Atul Khurana, et al.
Udgivet: (2024-11-01)

Real-Life Data on the Safety of Pasireotide in Acromegaly: Insights from EudraVigilance
af: Ioana Rada Popa Ilie, et al.
Udgivet: (2024-12-01)

A Pharmacovigilance Study on the Safety of Axicabtagene Ciloleucel Based on Spontaneous Reports from the EudraVigilance Database
af: Concetta Rafaniello, et al.
Udgivet: (2023-08-01)

Safety Monitoring of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years by Using EudraVigilance Pharmacovigilance Database: The CoVaxChild Study
af: Alessia Zinzi, et al.
Udgivet: (2023-02-01)

Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database
af: Shruti Rastogi, et al.
Udgivet: (2022-02-01)

Post-Marketing Surveillance of Statins—A Descriptive Analysis of Psychiatric Adverse Reactions in EudraVigilance
af: Gabriela Pop, et al.
Udgivet: (2022-12-01)

A Descriptive Analysis of Direct Oral Anticoagulant Drugs Dosing Errors Based on Spontaneous Reports from the EudraVigilance Database
af: Claudiu Morgovan, et al.
Udgivet: (2023-03-01)

A Pharmacovigilance Study Regarding the Risk of Antibiotic-Associated <i>Clostridioides difficile</i> Infection Based on Reports from the EudraVigilance Database: Analysis of Some of the Most Used Antibiotics in Intensive Care Units
af: Bogdan Ioan Vintila, et al.
Udgivet: (2023-11-01)

BNT162b2 COVID-19 Vaccine Safety among Healthcare Workers of a Tertiary Hospital in Italy
af: Flavia Beccia, et al.
Udgivet: (2023-02-01)

Safety of Inclisiran: A Disproportionality Analysis from the EudraVigilance Database
af: Giuseppe Cicala, et al.
Udgivet: (2024-10-01)

Seriousness and outcomes of reported adverse drug reactions in old and new antiseizure medications: a pharmacovigilance study using EudraVigilance database
af: Michael Magdy Fahmy Girgis, et al.
Udgivet: (2024-07-01)

Polymyalgia Rheumatica After COVID-19 Vaccination: Data from the EudraVigilance Database
af: Cláudia Pinto Oliveira, et al.
Udgivet: (2024-04-01)

Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database
af: Fabrizio Calapai, et al.
Udgivet: (2023-07-01)

Suspected oncologic adverse reactions associated with interleukin‐23 inhibitors in EudraVigilance: Comparative study and gender distribution
af: Fabrizio Calapai, et al.
Udgivet: (2023-10-01)

Cytokine and Chemokine Production in Mice Inoculated with NVX-CoV2373 (Nuvaxovid<sup>®</sup>) in Comparison with Omicron BA.4/5 Bivalent BNT162b2 (Comirnaty<sup>®</sup>)
af: Tetsuo Nakayama, et al.
Udgivet: (2023-11-01)

Comparative Analyses of the Safety Profiles of Vitamin D Receptor Agonists: A Pharmacovigilance Study Based on the EudraVigilance Database
af: Zsolt Gáll, et al.
Udgivet: (2024-12-01)

Reduced Antibody Acquisition with Increasing Age following Vaccination with BNT162b2: Results from Two Longitudinal Cohort Studies in The Netherlands
af: Lotus Leonie van den Hoogen, et al.
Udgivet: (2022-09-01)

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
af: Stilla Bauernfeind, et al.
Udgivet: (2021-09-01)

Comparative effectiveness and safety of BNT162b2 and CoronaVac in Hong Kong: A target trial emulation
af: Eric Yuk Fai Wan, et al.
Udgivet: (2024-09-01)

Pulmonary Embolism after Vaccination with the COVID-19 Vaccine (Pfizer, BNT162b2): A Case Report
af: Eun-Ju Kim, et al.
Udgivet: (2023-06-01)

Safety Profiles Related to Dosing Errors of Rapid-Acting Insulin Analogs: A Comparative Analysis Using the EudraVigilance Database
af: Ioana Rada Popa Ilie, et al.
Udgivet: (2024-10-01)

Syncope following Pfizer BioNTech (bnt162b2) vaccination unmasking Brugada syndrome
af: Mohammad Altermanini, et al.
Udgivet: (2023-08-01)

Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccineResearch in context
af: Ivan Odak, et al.
Udgivet: (2024-01-01)

Association between Immunoglobulin G Levels and Adverse Effects Following Vaccination with the BNT162b2 Vaccine among Japanese Healthcare Workers
af: Jun Otani, et al.
Udgivet: (2021-10-01)

Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan
af: Toshio Naito, et al.
Udgivet: (2022-01-01)

Pyoderma Gangrenosum Induced by BNT162b2 COVID-19 Vaccine in a Healthy Adult
af: Mazin Barry, et al.
Udgivet: (2022-01-01)

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
af: Louise Murdoch, et al.
Udgivet: (2023-09-01)

Drug–Drug Interactions of Selective Serotonin Reuptake Inhibitors: A Pharmacovigilance Study on Real-World Evidence from the EudraVigilance Database
af: Carmen Maximiliana Dobrea, et al.
Udgivet: (2024-09-01)

Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine
af: Itzchak Levy, et al.
Udgivet: (2022-07-01)

Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination
af: Stilla Bauernfeind, et al.
Udgivet: (2022-09-01)

Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination
af: Timothy E. Albertson, et al.
Udgivet: (2024-03-01)

Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis
af: Eli Magen, et al.
Udgivet: (2022-07-01)

Vaccine Vigilance System: Considerations on the Effectiveness of Vigilance Data Use in COVID-19 Vaccination
af: Diana Araja, et al.
Udgivet: (2022-12-01)

BNT162b2 COVID-19 Vaccination and Its Effect on Blood Pressure
af: Toh Leong Tan, et al.
Udgivet: (2022-12-01)

Effectiveness of BNT162b2 COVID-19 Vaccine in Preventing Severe Symptomatic Infection among Healthcare Workers
af: Efrén Murillo-Zamora, et al.
Udgivet: (2021-07-01)

Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose
af: Nesrin Gareayaghi, et al.
Udgivet: (2022-10-01)

Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2
af: Jean-Louis Bayart, et al.
Udgivet: (2021-06-01)

Safety and Humoral and Cellular Immunogenicity of the BNT162b2 SARS-CoV-2 Vaccine in Liver-Transplanted Adolescents Compared to Healthy Adolescents
af: Palittiya Sintusek, et al.
Udgivet: (2022-08-01)

Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients
af: Michael Kwan Leung Yu, et al.
Udgivet: (2024-12-01)